Customized phage therapies to eradicate
harmful bacteria in chronic diseases
BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
- Data presented at the presidential plenary translational session of the AASLD conference - Results demonstrate in vivo use of a phage cocktail effectively eradicated a bacteria hypothesized to be a disease modifying target in Primary Sclerosing Cholangitis (PSC)...
BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director
Ness Ziona, Israel – November 4, 2019, – BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies, today announced the election of Russell G. Greig, Ph.D., as Chairman of the Board of Directors and Lynne Sullivan as Board...
Combined company renamed BiomX Inc. will trade on the NYSE American stock exchange under the symbol PHGE beginning October 29, 2019 NEW YORK and Ness Ziona, Israel, October 28, 2019 -- Chardan Healthcare Acquisition Corp. (NYSE: CHAC), a special purpose acquisition...